Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population.
Adult
Aged
Carcinoma
/ genetics
Female
GTP Phosphohydrolases
/ genetics
Humans
Ki-67 Antigen
/ genetics
Male
Membrane Proteins
/ genetics
Middle Aged
Mutation
Neoadjuvant Therapy
Proto-Oncogene Proteins B-raf
/ genetics
Proto-Oncogene Proteins p21(ras)
/ genetics
Receptor, ErbB-2
/ genetics
Rectal Neoplasms
/ genetics
Treatment Outcome
Tumor Suppressor Protein p53
/ genetics
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
08
2019
revised:
30
10
2019
accepted:
24
12
2019
entrez:
31
1
2020
pubmed:
31
1
2020
medline:
30
9
2020
Statut:
epublish
Résumé
Pathologic features depending on tumor response to preoperative chemoradiotherapy are important to determine the outcomes in patients with rectal cancer. Evaluating the potential predictive roles of biomarker expression and their prognostic impact is a promising challenge. We reported here the immunohistochemical staining of a panel marker of mismatch repair protein (MMR), Ki67, HER-2, and p53. Additionally, identification of somatic mutations of KRAS, NRAS, and BRAF genes were performed by direct sequencing and pyrosequencing in pretreated biopsy tissues from 57 patients diagnosed for rectal cancer. Clinical features and pathological criteria for postneoadjuvant treatment surgical resection specimen's data were collected. Immunohistochemical expression and mutational status were correlated with therapeutic response, overall survival, and disease progression. The mean age of patients was 56 years. Seven (12.3%) out of 57 patients had a complete therapeutic response. Our analysis showed that when using complete therapeutic response (Dworak 4) and incomplete therapeutic response (Dworak 3, 2, and 1) as grouping factor, high p53 expression at the pretreatment biopsy was significantly associated to an incomplete response (
Identifiants
pubmed: 31998419
doi: 10.1155/2020/8459303
pmc: PMC6977322
doi:
Substances chimiques
KRAS protein, human
0
Ki-67 Antigen
0
Membrane Proteins
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
GTP Phosphohydrolases
EC 3.6.1.-
NRAS protein, human
EC 3.6.1.-
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8459303Informations de copyright
Copyright © 2020 Ihsane El Otmani et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper.
Références
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Cancer Sci. 2014 Jul;105(7):818-24
pubmed: 24730770
Dis Colon Rectum. 2014 May;57(5):592-601
pubmed: 24819099
Oncology. 2000;58(1):52-9
pubmed: 10644941
Br J Cancer. 2014 Nov 11;111(10):1977-84
pubmed: 25211663
Nat Rev Clin Oncol. 2009 Sep;6(9):519-27
pubmed: 19636327
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
World J Gastroenterol. 2008 Feb 21;14(7):1060-6
pubmed: 18286688
Cancer Res. 2010 Jul 15;70(14):5901-11
pubmed: 20570890
Medicine (Baltimore). 2016 Jan;95(3):e2582
pubmed: 26817916
Br J Cancer. 2010 Feb 16;102(4):693-703
pubmed: 20147967
Medicine (Baltimore). 2015 Aug;94(31):e1284
pubmed: 26252300
Anticancer Res. 2004 Sep-Oct;24(5B):3161-7
pubmed: 15510606
Ann Surg Oncol. 2013 Jul;20(7):2166-71
pubmed: 23456389
Radiother Oncol. 2010 Jan;94(1):76-81
pubmed: 19913317
Clin Cancer Res. 2001 Apr;7(4):999-1009
pubmed: 11309351
Pathol Res Pract. 2019 May;215(5):910-917
pubmed: 30772061
J Clin Oncol. 2008 Jun 1;26(16):2690-8
pubmed: 18509181
Rom J Morphol Embryol. 2018;59(1):29-42
pubmed: 29940609
Cancer Res. 2002 May 1;62(9):2447-54
pubmed: 11980631
Dis Colon Rectum. 2015 Jun;58(6):556-65
pubmed: 25944427
Cancer. 2000 Apr 1;88(7):1739-57
pubmed: 10738234
Eur J Surg Oncol. 2003 Apr;29(3):201-12
pubmed: 12657227
Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1455-61
pubmed: 17445998
Colorectal Dis. 2013 Sep;15(9):1130-9
pubmed: 23581977
J Oncol Pract. 2015 Jul;11(4):e476-86
pubmed: 26080831
Br J Cancer. 2001 Sep 1;85(5):692-6
pubmed: 11531254
Virchows Arch. 1995;427(3):229-41
pubmed: 7496591
Genes Chromosomes Cancer. 2011 May;50(5):307-12
pubmed: 21305640
J Pathol. 1998 Apr;184(4):348-50
pubmed: 9664899
Front Biosci (Schol Ed). 2014 Jan 01;6:110-9
pubmed: 24389265
Dig Liver Dis. 2010 Oct;42(10):679-84
pubmed: 20227932
J Clin Oncol. 1999 May;17(5):1364-74
pubmed: 10334520
J Natl Cancer Inst. 1998 May 6;90(9):675-84
pubmed: 9586664
Cell Oncol (Dordr). 2013 Jul;36(4):311-21
pubmed: 23722824
Ann Surg Oncol. 2001 Jun;8(5):418-24
pubmed: 11407516
Medicine (Baltimore). 2015 Nov;94(47):e2106
pubmed: 26632727
Ann Pathol. 2014 Oct;34(5):352-65
pubmed: 25439988
J Gastroenterol Hepatol. 2011 Dec;26(12):1733-9
pubmed: 21615788
Dis Markers. 2010;29(5):207-12
pubmed: 21206005
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
BMC Cancer. 2006 May 10;6:124
pubmed: 16686938
J Cell Physiol. 2000 Mar;182(3):311-22
pubmed: 10653597
J Clin Oncol. 2003 Mar 15;21(6):1174-9
pubmed: 12637487
J Ky Med Assoc. 2007 Jan;105(1):18-22
pubmed: 17310874
Dis Colon Rectum. 2017 Jul;60(7):697-705
pubmed: 28594719
J Clin Oncol. 2012 Jun 1;30(16):1926-33
pubmed: 22529255
Curr Treat Options Oncol. 2017 Sep 25;18(10):64
pubmed: 28948490
Cancer Biol Ther. 2006 Aug;5(8):928-32
pubmed: 16969076